Themes / Group
Inactive · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Gene Editing Therapies

THE TRADER READRecurring relationship, inactive in the latest snapshot

6 of 8 measured SPY-adjusted paths align to the downside across 6.0 effective names. Capital-flow agreement is 15%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth3 up · 5 down-1.5% median path versus SPY
Capital-flow alignment15%Price breadth is not yet confirmed by flow
Activity nowCalmActivity score 20/100 · lift 0.8×
Evidence depth4 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 10:35–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceVKTX registered the first material downside path

    -0.94% session path at the threshold · VKTX

  2. 5-minute inferenceSMMT registered a material downside path

    -2.27% session path at the threshold · SMMT

  3. 5-minute inferenceROIV registered a material downside path

    -1.12% session path at the threshold · ROIV

  4. 5-minute inferenceIBRX registered a material downside path

    -1.21% session path at the threshold · IBRX

2 earlier filing context receipts

WED, FEB 4ARWR filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

WED, JUL 22SMMT filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

SPY-adjusted 5m paths

Observed movement is broad across 6.0 effective names. VKTX represents 24.3% of absolute path energy; 6 of 8 members align with the down relative path.

ConstructionBroad24.3% from the largest path
Effective names6.0 / 8Movement diversity after concentration
Direction breadth6/8 aligneddownside relative path · 1 counter-moving
Largest moverVKTX 24.3%44.8% from the top two paths
VKTX24.3%Aligned contributor · path -2.93% · basket -0.37pp
SMMT20.5%Aligned contributor · path -2.47% · basket -0.31pp
BBIO14.3%Aligned contributor · path -1.72% · basket -0.21pp
ROIV14.0%Aligned contributor · path -1.69% · basket -0.21pp
CGON11.2%Counter-move · path +1.34% · basket +0.17pp
IBRX10.9%Aligned contributor · path -1.31% · basket -0.16pp
BEAM3.6%Aligned contributor · path -0.44% · basket -0.06pp
ARWR1.1%Flat / inactive path · path -0.14% · basket -0.02pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. VKTX moved lower firstFirst member to clear the material path threshold · path -0.94%
  2. SMMT registered a material lower path0m after the first price move · path -2.27%
  3. ROIV registered a material lower path0m after the first price move · path -1.12%
  4. IBRX registered a material lower path0m after the first price move · path -1.21%
  5. BBIO registered a material lower path5m after the first price move · path -0.51%
  6. ARWR registered a material lower path5m after the first price move · path -0.39%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

SPY-adjusted
Aug 21 · 10:35 ETMove visible 11:05 ETAug 21 · 15:55 ET
Group median -1.50%Strongest relative path CGONWeakest relative path VKTX

Observed member paths adjusted against SPY. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

8/8 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across ARWR, BBIO, BEAM, CGON, IBRX, ROIV, SMMT, VKTX.

product pipeline / R&D affecting expense

“The increase in third-party research and development expenses for the three and six months ended June 30, 2026, was primarily driven by a $36.9 million and $68.4 million increase in clinical trial related expenses, respectively, a $6.3 million and $26.2 million increase in expenses related to manufacturing and purchasing of clinical trial related materials as a result of increased enrollment in our HARMONi-3, HARMONi-7, and HARMONi-GI3 trials, respectively, and a $3.3 million and $5.7 million increase in other external research and development expenses, respectively.”

SMMT 10-Q · 2026-07-23
credit / rates affecting interest expense

“Interest Expense Interest expense decreased for the year ending December 31, 2025 compared to the same period in the prior year, due to the repayment in full of the promissory note in October 2024.”

SMMT 10-K · 2026-02-23
product pipeline / R&D

“An entity that takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is 10 typically referred to as a “sponsor” or “applicant.” Biological products used for the prevention, treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except that the section of the FDCA that governs the approval of new drug applications (“NDAs”) does not apply to the approval of biological products.”

SMMT 10-K · 2026-02-23
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming

No qualified cross-asset lead/lag link is available for this group.

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

RLYBRelationship only · live confirmation unavailable

BBIO · text peer

MRKNot confirming

ROIV · text peer

REPLNot confirming

ROIV · text peer

IOVANot confirming

IBRX · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
SMMTCGONVKTXROIVBEAMBBIOIBRXARWR

5/8 active3 rising · 5 falling

MemberUnusual activityToday's moveRead now
SMMTSummit Therapeutics Inc.
Most unusual · 100/100
+5.9%
Aligned path contributorActive in 0% of observed group sessions
CGONCG Oncology, Inc.
Elevated · 54/100
+2.8%
Counter-move / dispersionActive in 40% of observed group sessions
VKTXViking Therapeutics, Inc.
Elevated · 52/100
-1.5%
Aligned price + flowActive in 0% of observed group sessions
ROIVRoivant Sciences Ltd.
Elevated · 46/100
-1.4%
Aligned price + flowActive in 80% of observed group sessions
BEAMBeam Therapeutics Inc.
Elevated · 42/100
+4.9%
Aligned path contributorActive in 60% of observed group sessions
BBIOBridgeBio Pharma, Inc.
Quiet · 39/100
-1.8%
Watch / laggardActive in 40% of observed group sessions
IBRXImmunityBio, Inc.
Quiet · 33/100
-0.6%
Watch / laggardActive in 20% of observed group sessions
ARWRArrowhead Pharmaceuticals, Inc.
Quiet · 27/100
-0.4%
Watch / laggardActive in 0% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
SMMTSummit Therapeutics Inc.Most unusual+5.9%0% of 5 sessionsMost unusual activity in this snapshot; performance direction may differ.
CGONCG Oncology, Inc.Participating+2.8%40% of 5 sessionsPrice participation with accumulating signed flow.
VKTXViking Therapeutics, Inc.Participating-1.5%0% of 5 sessionsPrice participation with accumulating signed flow.
ROIVRoivant Sciences Ltd.Participating-1.4%80% of 5 sessionsPrice participation with accumulating signed flow.
BEAMBeam Therapeutics Inc.Participating+4.9%60% of 5 sessionsPrice participation is not yet confirmed by per-name flow.
BBIOBridgeBio Pharma, Inc.Quiet / lagging-1.8%40% of 5 sessionsNot participating yet; a breadth test or a genuine divergence.
IBRXImmunityBio, Inc.Quiet / lagging-0.6%20% of 5 sessionsNot participating yet; a breadth test or a genuine divergence.
ARWRArrowhead Pharmaceuticals, Inc.Quiet / lagging-0.4%0% of 5 sessionsNot participating yet; a breadth test or a genuine divergence.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Live outcome ledger collecting

0/0 events completed

No completed point-in-time outcome is available yet. New live confirmations are now retained with their exact observation timestamp; statistics appear only after the corresponding candles complete.

Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 4 completed episodes across 5 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support17 daysHow often the cohort identity was observed
Completed episodes4Separate periods of broad group activity
Active sessions5Completed session observations, not trades
2026-08-111 active session100% composition consistency through the episode
2026-08-061 active session100% composition consistency through the episode
2026-07-30 → 2026-07-312 active sessions25% composition consistency through the episode
2026-07-231 active session100% composition consistency through the episode
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
ROIV80% · 4 episodes
BEAM60% · 2 episodes
BBIO40% · 2 episodes
CGON40% · 2 episodes
IBRX20% · 1 episode
ARWR0% · 0 episodes
SMMT0% · 0 episodes
VKTX0% · 0 episodes